A mechanistic science of human flourishing
Designing the next generation of therapeutics for well-being enhancement
AI is radically accelerating all parts of the drug development pipeline, from discovery to experimental validation. What used to take a decade and a billion dollars is becoming faster and cheaper, and soon enough by orders of magnitude. We are on a mission to leverage breakthroughs in AI for developing better therapeutics for alleviating pain and improving well-being.
Nearly every compound that reliably enhances well-being was discovered before 1990. The chemical space is all but uncharted. The first drug to sustainably raise the hedonic baseline of humans will be the most important medicine ever made.
Team
Curran Jansens
Co-Founder & CEO
Max Novendstern
Co-Founder & Chairman
David Pearce
Advisor
Michael Johnson
Advisor
Kristian Rönn
Advisor